Navigation Links
MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
Date:8/4/2008

VALENCIA, Calif., Aug. 4 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2008 second quarter financial results on Monday, August 11, 2008 at 4:00 p.m. EDT.

Management of the Company will host a conference call to discuss the second quarter financial results, clinical progress and other Company developments at 5:00 p.m. EDT on Monday, August 11, 2008. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Matthew Pfeffer and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com.

A telephone replay of the call will be accessible for approximately fourteen days following completion of the call by dialing (800) 219-6350 or (402) 220-3904. A replay will also be available on MannKind's website for fourteen days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere Insulin System, is currently in Phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. MannKind to Present at the Wachovia 2008 Healthcare Conference
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
8. MannKind Corporation Response to Recent Market Events
9. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
10. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
11. MannKind to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... Linda, Ca (PRWEB) , ... April 27, 2017 ... ... hear from a practicing internist, who will review how testing for 1,25-Dihydroxyvitamin D ... that prompt ordering of 25-OH-vitamin D and 1,25 dihydroxyvitamin D. , Dr. Gregory ...
(Date:4/27/2017)... April 27, 2017  Pendant Biosciences, Inc. (formerly Nanoferix, ... modification and drug delivery technologies, today announced that it ... @ Toronto . ... Pendant Biosciences, noted, "We are excited to become part ... community, and are honored to be the first ...
(Date:4/26/2017)... ... ... LABS, Inc. (LABS) announced in December 2016 that two new Zika ... Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific for IgM and IgG ZIKV ... donors under an Investigational New Drug (IND) study protocol. , Now, as part ...
(Date:4/25/2017)... ... ... As part of the Stago EdVantage Virtual University Virtual Event, ... order to illuminate this clinical problem for people unfamiliar with the topic. , DIC ... high degree of morbidity and mortality. DIC is a confusing disorder from both diagnostic ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):